These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10840195)

  • 1. Cellular delivery of antisense oligonucleotides.
    Lebedeva I; Benimetskaya L; Stein CA; Vilenchik M
    Eur J Pharm Biopharm; 2000 Jul; 50(1):101-19. PubMed ID: 10840195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell membranes as barriers for the use of antisense therapeutic agents.
    Jääskeläinen I; Urtti A
    Mini Rev Med Chem; 2002 Aug; 2(4):307-18. PubMed ID: 12370052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of delivery systems to improve target efficacy of oligonucleotides.
    Shoji Y; Nakashima H
    Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells.
    Lappalainen K; Urtti A; Jääskeläinen I; Syrjänen K; Syrjänen S
    Antiviral Res; 1994 Feb; 23(2):119-30. PubMed ID: 8147581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular uptake and intracellular fate of antisense oligonucleotides.
    Thierry AR; Vives E; Richard JP; Prevot P; Martinand-Mari C; Robbins I; Lebleu B
    Curr Opin Mol Ther; 2003 Apr; 5(2):133-8. PubMed ID: 12772502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes.
    Miyano-Kurosaki N; Barnor JS; Takeuchi H; Owada T; Nakashima H; Yamamoto N; Matsuzaki T; Shimada F; Takaku H
    Antivir Chem Chemother; 2004 Mar; 15(2):93-100. PubMed ID: 15185727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomes as a drug delivery system for antisense oligonucleotides.
    Juliano RL; Akhtar S
    Antisense Res Dev; 1992; 2(2):165-76. PubMed ID: 1392538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antisense oligonucleotide drug delivery systems.
    Weyermann J; Lochmann D; Zimmer A
    J Control Release; 2004 Dec; 100(3):411-23. PubMed ID: 15567506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
    Weyermann J; Lochmann D; Georgens C; Zimmer A
    Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells.
    Lappalainen K; Urtti A; Söderling E; Jääskeläinen I; Syrjänen K; Syrjänen S
    Biochim Biophys Acta; 1994 Dec; 1196(2):201-8. PubMed ID: 7841184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of antisense as a CNS therapeutic.
    Godfray J; Estibeiro P
    Expert Opin Ther Targets; 2003 Jun; 7(3):363-76. PubMed ID: 12783572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The delivery of antisense therapeutics.
    Akhtar S; Hughes MD; Khan A; Bibby M; Hussain M; Nawaz Q; Double J; Sayyed P
    Adv Drug Deliv Rev; 2000 Oct; 44(1):3-21. PubMed ID: 11035194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
    Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
    J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
    Phillips MI
    Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of antisense oligonucleotides using cholesterol-modified sense dendrimers and cationic lipids.
    Chaltin P; Margineanu A; Marchand D; Van Aerschot A; Rozenski J; De Schryver F; Herrmann A; Müllen K; Juliano R; Fisher MH; Kang H; De Feyter S; Herdewijn P
    Bioconjug Chem; 2005; 16(4):827-36. PubMed ID: 16029024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides.
    Jääskeläinen I; Peltola S; Honkakoski P; Mönkkönen J; Urtti A
    Eur J Pharm Sci; 2000 May; 10(3):187-93. PubMed ID: 10767596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty.
    Pickering JG; Isner JM; Ford CM; Weir L; Lazarovits A; Rocnik EF; Chow LH
    Circulation; 1996 Feb; 93(4):772-80. PubMed ID: 8641007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes.
    Kanamaru T; Takagi T; Takakura Y; Hashida M
    J Drug Target; 1998; 5(4):235-46. PubMed ID: 9713974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.